IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.

@article{Yang2015IDHMA,
  title={IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.},
  author={Pei Yang and Wei Ping Zhang and Y Y Wang and Xiaoxia Peng and Baoshi Chen and Xiaoguang Qiu and Guilin Li and Shouwei Li and Chenxing Wu and Kun Yao and Wen-Bin Li and Wei Yan and Jie Li and Yongping You and Clark C Chen and Tao Jiang},
  journal={Oncotarget},
  year={2015},
  volume={6 38},
  pages={40896-906}
}
BACKGROUND The relative contribution of isocitrate dehydrogenase mutations (mIDH) and O6-methylguanine-DNA methyltransferase promoter methylation (methMGMT) as biomarkers in glioblastoma remain poorly understood. METHODS We investigated the association between methMGMT and mIDH with progression free survival and overall survival in a prospectively collected molecular registry of 274 glioblastoma patients. RESULTS For glioblastoma patients who underwent Temozolomide and Radiation Therapy, OS… CONTINUE READING